AbbVie Buys Apogee for $10.9B; ABBV Pops 6%
AbbVie agreed to buy Apogee Therapeutics for $10.9B all-cash at a 49% premium, adding IL-13 candidate zumilokibart to challenge Dupixent. ABBV rose 6%.
atopic dermatitis
AbbVie agreed to buy Apogee Therapeutics for $10.9B all-cash at a 49% premium, adding IL-13 candidate zumilokibart to challenge Dupixent. ABBV rose 6%.